Pfizer plans to spend $650 million on a 220,000-square-foot Manufacturing Technology Center at its Groton, Connecticut research campus, bringing drug production back to a site where the company wound down manufacturing almost two decades ago. Construction is slated to begin in the second quarter of 2027, with startup targeted for mid-2031.
The building will make clinical active pharmaceutical ingredients and finished drug products for trials that Pfizer sponsors around the world. Rather than hiring a new workforce, the company will move staff now spread across other buildings on the campus into the center, according to AdvanceCT, the state’s nonprofit economic development corporation, which announced the project on November 5.
Why Is Manufacturing Coming Back to Groton?
Pfizer phased out commercial manufacturing in Groton by the end of 2008, eliminating about 300 jobs so its research operations could expand on the site. The new center serves a different purpose, producing material for clinical studies rather than for commercial markets.
The announcement also follows a lean stretch for the campus. Over the past 15 years Pfizer moved research units out of Groton and demolished surplus buildings, including its former 750,000-square-foot research headquarters, and it announced further layoffs there in 2023 as part of a companywide cost-cutting program.
Timing may matter too. In September 2025, Pfizer reached an agreement with the Trump administration that pledged $70 billion for U.S. research, development and capital projects in return for a three-year reprieve from proposed pharmaceutical tariffs. Pfizer has not said publicly whether the Groton center counts toward that commitment.
What Will the Center Produce?
The facility is meant to link early drug discovery with the manufacturing steps needed to move candidates into human trials. Groton site head Raja Mangipudy said the center will strengthen Pfizer’s ability to support clinical research and the development of new medicines worldwide.
That supply chain is substantial. Pfizer’s latest pipeline update, published this month, lists 89 candidates in development, and the company says nearly every medicine it develops passes through Groton at some stage.
At roughly 220,000 square feet, the center is close to the size of four American football fields. It would add about a tenth to the existing 2.17 million square feet of laboratory and office space on the 175-acre campus beside the Thames River, which Pfizer opened in 1959. The announcement did not name an architect, engineer or general contractor.
How Many Jobs Will It Bring?
No new job figure has been announced, because the project consolidates existing roles. The campus is already one of the largest employers in the area: the Town of Groton recorded Pfizer as its second largest taxpayer in fiscal 2025, with about 4,000 employees, and Pfizer cited a similar headcount in testimony to the Connecticut General Assembly in March.
State and local officials framed the investment as a commitment to the existing workforce. AdvanceCT President and CEO John Bourdeaux called it “a significant vote of confidence in Groton,” while Daniel O’Keefe, commissioner of the Connecticut Department of Economic and Community Development, tied it to the state’s strategy of backing industries where it already has an edge.
The City of Groton has pledged to support Pfizer through planning, construction and startup. Its mayor, Jill Rusk, described the center as a long-term commitment to the city, and Town of Groton Mayor Juliette Parker called Pfizer’s presence a major asset for southeastern Connecticut.
Clinical research is also shaping healthcare construction elsewhere, as at the $105 million Tennessee Oncology center completed by Turner Construction in Nashville, which includes a dedicated drug development unit alongside its imaging, infusion and surgical oncology services.
Project Overview
- Project Name: Pfizer Groton Manufacturing Technology Center
- Developer and Owner: Pfizer Inc.
- Location: Pfizer research and development campus, Groton, Connecticut
- Project Type: Clinical pharmaceutical manufacturing facility
- Project Value: $650 million capital investment over five years
- Floor Area: About 220,000 sq ft
- Output: Clinical active pharmaceutical ingredients and drug products for Pfizer-sponsored trials
- Host Campus: 175 acres; 2.17 million sq ft of lab and office space; established 1959
- Construction Start: Second quarter of 2027 (planned)
- Operational Startup: Mid-2031 (targeted)
- Workforce: Consolidates existing Groton staff; no new job figure announced
- General Contractor: Not publicly disclosed
- Previous Manufacturing: Commercial production at Groton phased out by the end of 2008
Project Team
- Owner and Developer: Pfizer
- Economic Development Partner: AdvanceCT
- State Agency: Connecticut Department of Economic and Community Development
- Host Municipality: Town of Groton
- Host Municipality: City of Groton
- General Contractor: Not yet disclosed
Leave a Reply